论文部分内容阅读
目的对比分析替罗非班在急性心肌梗死急诊介入治疗不同使用时间对冠脉血流及近期预后的疗效。方法 58例急性心肌梗死患者,随机分为替罗非班早期使用组(早期组)和晚期使用组(晚期组),每组29例。两组患者在治疗的不同时期介入使用替罗非班,比较分析两组患者的治疗效果。结果早期组的TIMI帧数明显的低于晚期组(P<0.05);早期组Blush的3级率显著高于晚期组(P<0.01),肌酸激酶的峰值浓度也明显低于晚期组(P<0.05);早期组在术后的90 min ST下降幅度也大于晚期组(P<0.05)。结论在急性心肌梗死患者的急诊手术中使用替罗非班具有良好的治疗效果,且十分安全,在早期使用能改善冠脉血流,在近期预后中也有着显著疗效。
Objective To compare and analyze the curative effect of Tirofiban on coronary blood flow and short-term prognosis in patients with acute myocardial infarction at different times of interventional therapy. Methods 58 patients with acute myocardial infarction were randomly divided into early use group (early group) and late use group (late group), 29 patients in each group. Two groups of patients involved in the treatment of different stages of tirofiban, comparative analysis of the treatment effect of two groups of patients. Results The TIMI frame number in the early stage group was significantly lower than that in the late stage group (P <0.05). The third stage rate of Blush in the early stage group was significantly higher than that in the late stage group (P <0.01), and the peak concentration of creatine kinase was also significantly lower than that in the late stage group P <0.05). The decrease of ST in the early group after 90 min was also greater than that in the late group (P <0.05). Conclusions The use of tirofiban for emergency surgery in patients with acute myocardial infarction has a good therapeutic effect and is very safe. It can improve coronary blood flow in early stage and has significant curative effect in the near future.